Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „ruxolitinib“
Suchtreffer
Begriffe & Kennungen
Jakavi · 4.8 · 20 12.5% (grade ≥3, 11.1%) of patients in the ruxolitinib arm compared to 8.7% (grade ≥3, 6.0%) in the BAT arm
Eintrag öffnenJakavi · 4.8 · In patients receiving ruxolitinib mean decreases in haemoglobin reached a nadir of approximately 10 g/litre be
Eintrag öffnenJakavi · 4.8 · In phase 3 studies in MF, high lipase values were reported in 18.7% and 19.3% of patients in the ruxolitinib a
Eintrag öffnenOpzelura · 4.5 · Based on in vitro data, ruxolitinib is predominantly cleared by cytochrome P450 3A4 (CYP3A4) metabolism. Inter
Eintrag öffnenOpzelura · 4.5 · No interaction studies have been performed with topically administered ruxolitinib.
Eintrag öffnenOpzelura · 4.5 · The potential for interactions with ruxolitinib is considered to be low because of the limited systemic exposu
Eintrag öffnenOpzelura · 4.5 · The use of ruxolitinib cream in combination with other topical medicinal products used to treat vitiligo or at
Eintrag öffnenRuxolitinib Viatris
Eintrag öffnenRuxolitinib Viatris · 4.1 Therapeutic indications · 1
Eintrag öffnenRuxolitinib Viatris · 4.3 Contraindications · 1
Eintrag öffnenRuxolitinib Viatris · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenRuxolitinib Viatris · 4.3 · Pregnancy and lactation.
Eintrag öffnenRuxolitinib Viatris · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenRuxolitinib Viatris · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenRuxolitinib Viatris · 4.5 · 10 CYP3A4 inducers (such as, but not limited to, avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin
Eintrag öffnenRuxolitinib Viatris · 4.5 · 50% dose reduction should be considered when using medicinal products which are dual inhibitors of CYP2C9 and
Eintrag öffnenRuxolitinib Viatris · 4.5 · A study in healthy subjects indicated that ruxolitinib did not inhibit the metabolism of the oral CYP3A4 subst
Eintrag öffnenRuxolitinib Viatris · 4.5 · CYP3A4 inhibitors Strong CYP3A4 inhibitors (such as, but not limited to, boceprevir, clarithromycin, indinavir
Eintrag öffnenRuxolitinib Viatris · 4.5 · Dual CYP2C9 and CYP3A4 inhibitors In healthy subjects co-administration of ruxolitinib (10 mg single dose) wit
Eintrag öffnenRuxolitinib Viatris · 4.5 · Effects of ruxolitinib on other medicinal products
Eintrag öffnen